Regeneron Pharmaceuticals News

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

zacks.com · Jul 9, 2026

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

zacks.com · Jul 7, 2026

Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”

247wallst.com · Jul 7, 2026

Here's Why Regeneron (REGN) is a Strong Value Stock

zacks.com · Jul 7, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

zacks.com · Jul 7, 2026

Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term

zacks.com · Jul 2, 2026

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

fool.com · Jul 1, 2026

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

reuters.com · Jun 29, 2026

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

cnbc.com · Jun 29, 2026

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

fool.com · Jun 27, 2026

From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak

feeds.newsfilecorp.com · Jun 26, 2026

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

globenewswire.com · Jun 25, 2026

Is AbbVie a Buy After Its Purchase of Apogee?

fool.com · Jun 25, 2026

Regeneron's Applications for gMG Drug Accepted by FDA and EMA

zacks.com · Jun 23, 2026

2 Underrated Weight Loss Stocks to Buy and Hold

fool.com · Jun 23, 2026

Breakfast News: AbbVie's $11 Billion Pounce

fool.com · Jun 22, 2026

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

globenewswire.com · Jun 22, 2026

This Stock Is Up 58% This Year. Is It too Late to Buy?

fool.com · Jun 17, 2026

Here's Why Regeneron (REGN) is a Strong Value Stock

zacks.com · Jun 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

prnewswire.com · Jun 11, 2026

REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

gurufocus.com · Jun 10, 2026

REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

businesswire.com · Jun 10, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

globenewswire.com · Jun 9, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com · Jun 8, 2026

Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities

seekingalpha.com · Jun 8, 2026

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

zacks.com · Jun 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

prnewswire.com · Jun 4, 2026

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

globenewswire.com · Jun 4, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

globenewswire.com · Jun 2, 2026

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

zacks.com · Jun 1, 2026

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

zacks.com · Jun 1, 2026

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

zacks.com · May 29, 2026

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

globenewswire.com · May 28, 2026

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

247wallst.com · May 28, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

prnewswire.com · May 28, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

globenewswire.com · May 26, 2026

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

newsfilecorp.com · May 25, 2026

Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud Allegations

newsfilecorp.com · May 25, 2026

Here's Why Regeneron (REGN) is a Strong Value Stock

zacks.com · May 22, 2026

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

globenewswire.com · May 22, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

prnewswire.com · May 21, 2026

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

globenewswire.com · May 21, 2026

Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

globenewswire.com · May 21, 2026

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

gurufocus.com · May 20, 2026

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

businesswire.com · May 20, 2026

Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B

zacks.com · May 19, 2026

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

zacks.com · May 19, 2026

REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations

prnewswire.com · May 19, 2026

Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

prnewswire.com · May 18, 2026

Regeneron stock drops double digits on oncology trial failure

invezz.com · May 18, 2026

Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky About Fraud Investigation

newsfilecorp.com · May 18, 2026

Regeneron's Late-Stage Melanoma Study Misses Primary Goal

zacks.com · May 18, 2026

Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today

benzinga.com · May 18, 2026

Regeneron: Time To Forget Fianlimab (Rating Upgrade)

seekingalpha.com · May 18, 2026

Stock Futures Climb as Investors Monitor Middle East

schaeffersresearch.com · May 18, 2026

Regeneron faces Wall Street downgrades after high-profile melanoma drug fails to beat Merck's Keytruda

proactiveinvestors.com · May 18, 2026

Here Are Monday’s Top Wall Street Analyst Research Calls: Applied Materials, CoreWeave, Deckers Outdoor, F5, Lam Research, Salesforce, ServiceNow, Zscaler, and More

247wallst.com · May 18, 2026

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

barrons.com · May 18, 2026

Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints

wsj.com · May 18, 2026

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

globenewswire.com · May 18, 2026